AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 314.7 USD | -0.65% |
|
+0.59% | +9.27% |
| May. 16 | Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment | DJ |
| May. 16 | Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 33.02B | Sales 2025 * | 33.98B | Capitalization | 171B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.13B | Net income 2025 * | 6.61B | EV / Sales 2024 * | 6.65 x |
| Net Debt 2024 * | 48.47B | Net Debt 2025 * | 43.51B | EV / Sales 2025 * | 6.32 x |
| P/E ratio 2024 * |
40.7
x | P/E ratio 2025 * |
25
x | Employees | 26,700 |
| Yield 2024 * |
2.95% | Yield 2025 * |
3.17% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +0.84% | ||
| 1 week | +2.41% | ||
| Current month | +14.89% | ||
| 1 month | +18.53% | ||
| 3 months | +8.87% | ||
| 6 months | +15.27% | ||
| Current year | +9.27% |
1 week
307.06
321.44
1 month
260.68322.60
Current year
260.68329.72
1 year
211.71329.72
3 years
198.64329.72
5 years
166.68329.72
10 years
110.92329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 06-05-31 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 19-10-22 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | Dec. 17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 17-02-02 |
Ellen Kullman
BRD | Director/Board Member | 68 | 16-10-13 |
Robert Williams
BRD | Director/Board Member | 75 | 14-10-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 116 M€ | +16.08% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 314.7 | -1.35% | 2,367,243 |
| 24-05-15 | 319 | +2.45% | 3,466,160 |
| 24-05-14 | 311.4 | +0.96% | 1,631,250 |
| 24-05-13 | 308.4 | -0.55% | 1,558,472 |
| 24-05-10 | 310.2 | -0.87% | 2,611,880 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
319
USD
Average target price
314.6
USD
Spread / Average Target
-1.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.27% | 171B | |
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +0.45% | 163B |
- Stock Market
- Equities
- AMGN Stock
